

FINAL PROGRAM

6th CACHEXIA
CONFERENCE



MILAN, ITALY
8-10 December 2011


Congress organized by
the Society on Sarcopenia, Cachexia
and Wasting Disorders



www.cachexia.org



Therapeutic nutrition
with proven results



Make the right move for
patients with cancer...

*Cancer changes
everything.*

*It can interfere
with the important
everyday activities
in life, like dancing
with a favorite
partner.*



**High-level,
high-quality
protein**
Energy dense
Lower fat
EPA enriched

...to help them stay
in step with everyday life

ProSure is designed to help patients with cancer enjoy the activities of everyday life, even while fighting their disease. It is the first and only therapeutic nutrition with clinically demonstrated results:

- **Promotes weight gain¹⁻⁴**
- **Increases lean body mass^{3,5} and strength⁶**
- **Attenuates proinflammatory response^{1,3}**
- **Improves physical activity^{4,7,8} and quality of life^{1,6,8}**

* With 2 servings or more per day

References: 1. Guarcello M, et al. *Nutr Ther & Metab.* 2006;24:168-175. 2. Bayram I, et al. *Pediatr Blood Cancer.* In press 2009. 3. Ryan A, et al. In press. 2009. 4. van der Meij, et al. *Clin Nutr.* 2008;3:111(P193b). 5. Fearon K, et al. *Gut.* 2003;52:1479-1486. 6. von Meyenfeldt M, et al. *Proc Am Assoc Clin Oncol.* 2002;21:385A. 7. Moses A, et al. *Br J Can.* 2004;90:996-1002. 8. Bauer JD, et al. *Support Care Cancer.* 2005;13:270-274.

© 2009 Abbott Laboratories
5004 1108 0121 A1

*Begin to see results in 3 weeks**

 **Abbott**
A Promise for Life

CONTENTS

GENERAL INFORMATION

Welcome Message	5
Organization	6
CME Accreditation	6
Congress Information	7
Speaker Information	7
Poster Presenter Information	7

SCIENTIFIC PROGRAM

Thursday, December 8	9
Friday, December 9	10
Saturday, December 10	13
Faculty	15

EXHIBITION FLOOR PLAN	16
------------------------------	----

ACKNOWLEDGMENTS	18
------------------------	----



Thera
technologies



Leader in GRF

(growth hormone-releasing factor)

www.theratech.com



6th CACHEXIA CONFERENCE



Dear Colleague,

The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) is pleased to welcome you in Milan for the 6th Cachexia Conference.

As an international and multidisciplinary organization, the SCWD seeks to further research on cachexia and bring practical solutions to healthcare teams worldwide.

Since the first Cachexia Conference in Berlin in 2000, more than one thousand five hundred physicians from over twenty countries have attended our educational sessions.

This year, over sixty international speakers will join in one of the most attractive European cities, Milan. We expect this 6th Cachexia Conference to be a unique forum for all medical professionals dealing with cachexia in their disciplines.

The Scientific Committee worked hard to bring you an impressive three-day program. One day is dedicated to all aspects of Cachexia research. Then, the program has been designed in order to include both clinical and basic science tracks. Parallel sessions will permit various facets of cachexia to be explored. All will be able to contribute to general discussions in plenary sessions.

We would like to thank the local organizers and hope you will enjoy the conference.

Yours sincerely,

Giuseppe Rosano
Filippo Rossi Fanelli
Akio Inui
John Morley
Stefan Anker

ORGANIZATION



Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD)
3780 Old Norcross Road, Suite 103 PMB 501,
Duluth, Georgia 30096, USA
Contact : Monika Diek
Tel. +49 (0) 30 450-55 34 07
Fax +49 (0)30 450-55 39 51

CHAIRPERSONS

Giuseppe Rosano, Rome, Italy
Filippo Rossi Fanelli, Rome, Italy
Akio Inui, Kagoshima, Japan
John E. Morley, St. Louis, USA
Stefan D. Anker, Berlin, Germany

INTERNATIONAL SCIENTIFIC COMMITTEE

Stefan D. Anker, Berlin, Germany
Josep M. Argilés, Barcelona, Spain
Vickie Baracos, Edmonton, Canada
Andrew Coats, Norwich, UK
William J. Evans, Research Triangle Park, USA
Kenneth Fearon, Edinburgh, UK
Akio Inui, Kagoshima, Japan
John E. Morley, St. Louis, USA
Giuseppe Rosano, Rome, Italy
Filippo Rossi Fanelli, Rome, Italy

CONGRESS ORGANIZERS



MedEd Global Solutions
75 rue Guy Môquet, 92240 Malakoff, France
Tel +33 1 42 53 03 03 – Fax +33 1 42 53 03 02
E-mail: info@mededgs.com



The 6th Cachexia Conference was granted 15 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

CME Accreditation

European Accreditation is granted by the EACCME in order to allow participants who attend the above-mentioned activity to validate their credits in their own country.

Accreditation Statement

Accreditation by the EACCME confers the right to place the following statement in all communication materials including the registration website, the event programme and the certificate of attendance. The following statements must be used without revision:

- 'The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD)' (or) '6th Cachexia Conference' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

- The '6th Cachexia Conference' is designated for a maximum of (or 'for up to') 15 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

- EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

EACCME credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

CONGRESS INFORMATION

Congress Venue

ATA Hotel Executive
Viale Don Luigi Sturzo, 45
20154 Milan, Italy
Phone: +39 026 2941

Registration Desk

Registration Desk is located on the Garden Floor

Coffee Breaks

Thursday, December 8: 15:30 - 16:00
Friday, December 9: 10:00 - 11:00 and 15:30 - 16:30
Saturday, December 10: 09:30 - 10:30 and 14:45 - 15:15

Exhibition Area Opening Hours

Thursday, December 8: 13:30 - 20:00
Friday, December 9: 07:30-16:45
Saturday, December 10: 07:30-16:00

Attendee Desk

is open at the following times:

Thursday, December 8: 12:30-18:30
Friday, December 9: 08:00-18:30
Saturday, December 10: 08:00-17:00

Badges

For security purposes, delegates, accompanying persons and exhibitors must wear their name badges at all times.

Certificate of Attendance

All delegates may collect their certificate of attendance upon submission of the completed congress evaluation form.

Congress Bags

Congress bags will be distributed to all delegates upon badge collection.

SPEAKER INFORMATION

SPEAKER PREPARATION

Room: Slide Centre
Thursday, December 8: 12:00-19:00
Friday, December 9: 08:00-18:00
Saturday, December 10: 08:00-12:00

Please check with the congress staff in the Speaker Ready Room the day before you are scheduled to present. Computers will be available in the room as well as a technician should you need assistance with your presentation.

POSTER PRESENTER INFORMATION

Posters will be displayed during the conference days:
Thursday 8 December to Saturday 10 December.

Please refer to the schedule below for poster set-up and removal times:

Set-up		Dismantling	
Date	Time	Date	Time
Thursday, December 8	13:00-15:30	Saturday, December 10	15:15-16:30

SCIENTIFIC PROGRAM



13:30 - 15:30

OPENING SESSION

PLENARY ROOM

(talk no. 1: 25 min + 5 min discussion; all other talks: 17 min + 5 min discussion)

Chairs:

Giuseppe Rosano, Rome, Italy

Filippo Rossi Fanelli, Rome, Italy

Akio Inui, Kagoshima, Japan

WELCOME: Stefan Anker, Berlin, Germany

1. "Prometheus" basic science key note lecture: Cachexia as an energy wasting syndrome

Josep Argiles, Barcelona, Spain

2. Ghrelin – Important hormone and treatment option for cachexia

Florian Strasser, St Gallen, Switzerland

3. Accelerated loss of muscle in elderly people with inactivity

William Evans, Research Triangle Park, USA

4. Influence of muscle wasting on outcomes in the Western World

Vickie Baracos, Edmonton, Canada

5. Influence of muscle wasting on outcomes in Japan

Koichi Takayama, Fukuoka, Japan

15:30 - 16:00

Coffee break

16:00 - 17:45

PLENARY SESSION

PLENARY ROOM

(talk no. 6: 25 min + 5 min discussion; all other talks: 17 min + 5 min discussion)

Chairs:

William Evans, Research Triangle Park, USA

Ken Fearon, Edinburgh, UK

6. "Hippocrates" clinical science key note lecture: Sarcopenia vs. osteopenia/osteoporosis

Steven Cummings, San Francisco, USA

7. Update from Trialist Workshop 2010: cancer cachexia

Stefan Anker, Berlin, Germany

8. Update from Trialist Workshop 2010: sarcopenia definition

John Morley, St Louis, USA

9. How to measure undernutrition

Bruno Vellas, Toulouse, France

10. From sarcopenia to frailty

Tamara Harris, Bethesda, USA

18:30 - 19:15

WELCOME RECEPTION and POSTER viewing

POSTER AREA

7:15 - 08:15

**ONCOLOGY SUPPORTIVE CARE BREAKFAST SYMPOSIUM:
The cachexia, nausea and vomiting linkage throughout the cancer continuum**

SALA CRISTALLO

Chairs: Stefan Anker, Berlin, Germany**Speaker:** Harry Raftopoulos, New York, USA

08:30 - 10:00

**BASIC SCIENCE TRACK :
Regulation of muscle wasting**

PLENARY ROOM

(each talk: 14 min + 4 min discussion)

Chairs: Alan Russell, Research Triangle Park, USA
David Glass, Cambridge, USA

11. **Molecular control of atrophy in senescent muscle**
Paul Greenhaff, Nottingham, UK
12. **Nutritional control of muscle atrophy: role of essential amino acids**
Stephan von Haehling, Berlin, Germany
13. **Muscle wasting and sepsis: Data from the intensive care unit**
Lars Larsson, Uppsala, Sweden
14. **Role of beta-adrenergic signaling in skeletal muscle structure and function: implications for muscle wasting and disease**
Gordon Lynch, Melbourne, Australia
15. **Role of micro RNAs**
Thomas Thum, Hannover, Germany


**CLINICAL TRACK :
Sarcopenia & weight loss**

SALA CRISTALLO

(each talk: 14 min + 4 min discussion)

Chairs: Tamara Harris, Bethesda, USA
Cornel Sieber, Nuremberg, Germany

16. **Chronobiological considerations regarding the diagnosis, treatment and regulatory evaluation of cachexia & sarcopenia**
Gerald Sokol, Bethesda, MD, USA
17. **Ultrasound measurement of muscle quality and quantity in sarcopenia and disuse-atrophy**
Marco Narici, Manchester, UK
18. **Sarcopenia and frailty in the Orient**
Jean Woo, Hong Kong, China
19. **Managing sarcopenia and cachexia: the telemedicine viewpoint**
Friedrich Koehler, Berlin, Germany

10:00-11:00

Coffee break

10:10-11:00

POSTER SESSIONS

POSTER AREA (each presentation: 3 min including discussion)

P 01 Muscle wasting mechanisms I (posters 1-01 to 1-11)

Chairs: Josep Argiles, Thomas Thum

P 02 Cachexia mechanisms I (posters 2-01 to 2-14)

Chairs: Didier Attaix, Wolfram Doehner

P 03 Cancer cachexia I (posters 3-01 to 3-13)

Chairs: Florian Strasser, Stephan von Haehling

P 04 Cancer cachexia III (posters 4-01 to 4-12)

Chairs: Vickie Baracos, Maurizio Muscaritoli

P 05 Therapeutic development (clinical) (posters 8-01 to 8-15)

Chairs: Andrew Coats, Kamyar Kalantar-Zadeh

P 06 Therapeutic development (pre-clinical) I (posters 7-01 to 7-12)

Chairs: Samuel Breit, Francesco Dioguardi

11:00-12:30

**BASIC SCIENCE TRACK:
Cancer cachexia**

PLENARY ROOM

(each talk: 14 min + 4 min discussion)

Chairs: Giovanni Mantovani, Monserrato, Cagliari, Italy
Josep Argiles, Barcelona, Spain

20. **Review on animal models for cancer cachexia**
Jochen Springer, Berlin, Germany
21. **Recent advances in the biology of muscle wasting**
David Glass, Cambridge, USA
22. **Myostatin as target: 2011 update**
HQ Han, Thousand Oaks, USA
23. **Follistatin as a target for anabolic therapies**
Tianshun Xu, Research Triangle Park, USA
24. **Intra-myocellular fat as a determinate of poor functional status**
Bret Goodpaster, Pittsburgh, USA


**CLINICAL TRACK:
From herbal therapy to immune modulation**

SALA CRISTALLO

(talk no. 25: 15 min + 5 min discussion; all other talks: 14 min + 4 min discussion)

Chairs: Takashi Higashiguchi, Tsu, Japan
Michael Meguid, Syracuse, USA

25. **Japanese herbal medicine: an overview**
Akio Inui, Kagoshima, Japan
26. **Cachexia in Vietnam and traditional therapies**
Kim Anh Hoang, Hochiminh, Vietnam
27. **Immune therapy**
Hiroaki Nanba, Kobe, Japan
28. **Central mechanisms of lethargy in inflammation and cachexia**
Daniel Marks, Portland, USA
29. **Muscle phenotype shift and myopenia in stroke**
Wolfram Doehner, Berlin, Germany

12:45-13:45

INTERACTIVE LUNCH SEMINAR: Join the live Sarcopenia debate

SALA CRISTALLO

Facilitators: Maurizio Muscaritoli, Rome, Italy • Tommy Cederholm, Uppsala, Sweden

Share your views with peers during this debating session on the definition, screening and treatment of sarcopenia. This educational activity is organized by The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) and supported by an unrestricted educational grant provided by Nutricia.

Lunch will be provided

14:00-15:30

BASIC SCIENCE TRACK: From palliative care to exercise for cachexia**PLENARY ROOM**

(each talk: 14 min + 4 min discussion)

Chairs: Mitja Lainscak, Golnik, Slovenia
Florian Strasser, St. Gallen, Switzerland

- 30. **Palliative care for cachexia in Japan**
Takashi Higashiguchi, Tsu, Japan
- 31. **Palliative care for cancer & cachexia: survival impact**
Aminah Jatoi, Rochester, USA
- 32. **Pain and cachexia**
Yasuhito Uezono, Tokyo, Japan
- 33. **Integration of exercise in cachexia therapy**
Ramon Langen, Maastricht, The Netherlands
- 34. **Failure to thrive and renal cachexia: from pediatrics to geriatrics**
Robert Mak, La Jolla, La Jolla, USA

**CLINICAL TRACK: Update on anabolics & related therapies****SALA CRISTALLO**

(each talk: 10 min + 2 min discussion – followed by panel discussion of chairs & speakers)

Chairs: John Morley, St. Louis, USA
Kamyar Kalantar-Zadeh, Torrance, USA

- 35. **An update on skeletal muscle troponin activators and their potential application in muscle wasting and cachexia**
Fady Malik, San Francisco, USA
 - 36. **New therapies for cachexia/sarcopenia**
Ronenn Roubenoff, Boston, USA
 - 37. **Testosterone, sarcopenia and frailty**
Frederick Wu, Manchester, UK
 - 38. **SARMS**
Mitch Steiner, Memphis, USA
 - 39. **Ghrelin trial update**
John Friend, Bridgewater, USA
 - 40. **ACTAs**
Andrew Coats, Norwich, UK
- Panel discussion

15:30-16:30

Coffee break

15:40-16:30

POSTER SESSIONS**POSTER AREA** (each presentation: 3 min including discussion)

- P 07 **Muscle wasting mechanisms II (posters 1-12 to 1-23)**
Chairs: Denis Guttridge, Jochen Springer
- P 08 **Cachexia mechanisms II (posters 2-15 to 2-28)**
Chairs: Volker Adams, Alessandro Laviano
- P 09 **Cancer cachexia II (posters 3-14 to 3-25)**
Chairs: Kenneth Fearon, Stephan von Haehling

- P 10 **Nutrition & Appetite I (posters 6-01 to 6-12)**
Chairs: Wolfram Doehner, Michael Meguid
- P 11 **Sarcopenia/Myopenia/Frailty I (posters 5-01 to 5-12)**
Chairs: Angela Abbatecola, William Evans

16:30-18:15

JUDGES' CHOICE: Rapid oral presentations of selected abstracts (basic science)**PLENARY ROOM**

(talk no. 52: 10 min + 5 min discussion; all other talks: 5 min + 3 min discussion)

Chairs: Josep Argiles, Barcelona, Spain
Thomas Thum, Hannover, Germany

- 41. **Muscle actin is polyubiquitinated in C2C12 myotubes and human muscle biopsies and targeted for breakdown by the E3 ligase MuRF1 (1-14)**
Didier Attaix, Clermont-Ferrand, France
- 42. **The mitochondrial and neuromuscular systems are severely dysregulated in a rat sarcopenia model (5-17)**
Chikwendu Ibejunjo, Cambridge, USA
- 43. **Dln101 a naturally occurring ghrelin splice variant for the treatment of cachexia (7-09)**
Liat Mintz, East Brunswick, USA
- 44. **Msy-3/Csda coordinates repression of myogenic genes in muscle wasting (1-05)**
Libera Berghella, Rome, Italy
- 45. **Common Pathways in Cancer and Cardiac Cachexia (4-08)**
Michaela Schäfer, Heidelberg, Germany
- 46. **Tissue-protective effect of the non-hematopoietic erythropoietin analogues ARA284 and ARA286 in the treatment of cancer cachexia (7-20)**
Yulia Elkina, Berlin, Germany
- 47. **Leveraging the myostatin signaling pathway with small molecules: inhibitors of the activin receptors' kinase activity (7-10)**
Philip Turnbull, Research Triangle Park, USA
- 48. **Angiotensin II upregulates Pp2ca and inhibits AMPK signaling and energy balance leading to skeletal muscle wasting (2-21)**
Patrice Delafontaine, New Orleans, USA
- 49. **Gai2 signaling promotes skeletal muscle hypertrophy, myoblast differentiation and regeneration via PKC- and HDAC- dependent pathways (1-29)**
Mara Fornaro, Basel, Switzerland
- 50. **Total-body creatine pool size and skeletal muscle mass determination by D3-creatine dilution in rats (1-21)**
Stephen Stimpson, Research Triangle Park, USA
- 51. **mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass (7-19)**
Christopher Adams, Iowa City, USA
- 52. **Pancreatic cancer and ghrelin**
Chih-Yen Chen, Taipei, Taiwan

**CLINICAL SCIENCE TRACK: Late breaking clinical trials****SALA CRISTALLO**

(talk no. 53: 15 min + 3 min discussion; talk no. 54-59: 9 min + 3 min discussion; talk no. 60: 12 + 3 min)

Chairs: Stefan Anker, Berlin, Germany
Andrew Coats, Norwich, UK

- 53. **Overview: Regulatory considerations for treatment development in cachexia & sarcopenia**
Giuseppe Rosano, Rome, Italy
- 54. **GTx-024, a selective androgen receptor modulator (SARM), improves physical function in non-small cell lung cancer (NSCLC) patients with muscle wasting (8-07); In a Phase IIb trial GTx-024 overcomes the negative impact of > 8% weight loss on overall survival in non-small cell lung cancer (NSCLC) subjects (8-08)**
Shontelle Dodson, Memphis, USA
- 55. **Safety and tolerability of LGD-4033, a novel non-steroidal oral Selective Androgen Receptor Modulator (SARM), in healthy men (8-06)**
Eric Vajda, La Jolla, USA
- 56. **Randomised phase III clinical trial of a combined treatment with carnitine + celecoxib +/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome (8-05)**
Giovanni Mantovani, Monserrato, Cagliari, Italy
- 57. **Phase I/II trial of formoterol fumarate combined with megestrol acetate in patients with advanced malignancy (8-09)**
Carolyn Greig, Edinburgh, UK
- 58. **A phase I study of the effects of a true human, monoclonal antibody against interleukin 1a on lean body mass, nutritional intake and appetite in advanced cancer patients: preliminary findings (8-13)**
David Hui, Houston, USA
- 59. **Phase I/II Study of IP-1510 a novel interleukin-1 receptor antagonist in the Management of Cancer-Related Cachexia (8-12)**
Vasilis Paspaliaris, Melbourne, Australia
- 60. **Statistical considerations when designing clinical trials for sarcopenia / cachexia**
Bridget-Anne Kirwan, Nyon, Switzerland

Join the Cancer Cachexia Awareness Dinner

Friday, December 9

20:00 - 22:30

The SCWD has the pleasure of inviting you to attend its

Cancer Cachexia Awareness Dinner

at the Museo Diocesano

Ms. Lisa Niemi Swayze,

the wife of Patrick Swayze,

will participate in person to share how her life was impacted by the disease.

A professional moderator will facilitate discussions during dinner.

Venue: Museo Diocesano

Venue address: Corso di Porta Ticinese, 95 - 20123 Milan

Dress code: Cocktail Attire Requested

The dinner fees:

- a) for congress participant - 145€
- b) for non congress participant - 245€

08:00–09:30

**YOUNG INVESTIGATORS AWARD SESSION:
Clinical & Basic**

PLENARY ROOM

(talk no. 61: 15 min + 5 min discussion;
all other talks: 10 min + 4 min discussion)

Chairs: John Morley, St. Louis, USA
Maurizio Muscaritoli, Rome, Italy

Additional judges:

Vickie Baracos, Edmonton, Canada - Francesco Dioguardi,
Milan, Italy - Wolfram Doehner, Berlin, Germany - Ken Fearon,
Edinburgh, UK - Thomas Thum, Hannover, Germany

- 61. **An investigation of microRNAs in the skeletal muscle of cancer patients with cachexia (3-24)**
Nathan A. Stephens, Edinburgh, UK
- 62. **Mechanisms underlying anorexia in adjuvant arthritis: Focus on IL-1beta and orexigenic/anorexigenic neuropeptide mRNA expressions in hypothalamic nuclei (6-03)**
Andrea Stofkova, Prague, Czech Republic
- 63. **Low appendicular skeletal mass (ASM) with limited mobility predicts poor outcomes after 6-years in middle-aged African Americans (6-23)**
Theodore Malmstrom, St. Louis, USA
- 64. **Central nervous system control of inflammation induced muscle catabolism (1-28)**
Theodore P. Braun, Portland, USA
- 65. **Myostatin gene inactivation reduces skeletal muscle mass loss and tumor growth, and increases lifespan in mice with cancer cachexia (4-04)**
Yann S. Gallot, Lyon, France
- 66. **MT-102, a new "Anabolic Catabolic Transforming Agent", reverses effects of sarcopenia in a rat model (7-21)**
Mareike Pötsch, Berlin, Germany



Treatments, mechanisms and new science

SALA CRISTALLO

(each talk: 14 min + 4 min discussion)

Chairs: Denis Guttridge, Columbus, USA
Alessandro Laviano, Rome, Italy

- 67. **Peptide autoantibodies**
Serguei Fetissov, Rouen, France
- 68. **IGF-1 update 2011**
Volker Adams, Leipzig, Germany
- 69. **GDF-15 alias MIC-1 and anorexia/cachexia**
Samuel Breit, Sydney, Australia
- 70. **Cachexia in acute illness and viruses**
Carsten Tschöpe, Berlin, Germany
- 71. **Diabetes and muscle wasting**
Angela Abbatecola, Ancona, Italy

09:30–10:30

Coffee break

09:40–10:30

POSTER SESSIONS

POSTER AREA (each presentation: 3 min including discussion)

- P 12 **Cancer cachexia IV (posters 4-13 to 4-24)**
Chairs: Gerald Sokol, Stephan von Haehling
- P 13 **Muscle wasting mechanisms III (posters 1-24 to 1-34)**
Chairs: Serguei Fetissov, Daniel Marks
- P 14 **Sarcopenia/Myopenia/Frailty II (posters 5-13 to 5-25)**
Chairs: Tamara Harris, Cornel Sieber

- P 15 **Nutrition & Appetite II (posters 6-14 to 6-24)**
Chairs: Josep Argiles, Robert Mak
- P 16 **Therapeutic development (pre-clinical) II (posters 7-13 to 7-24)**
Chairs: David Glass, Jochen Springer

10:30–12:00

**BASIC SCIENCE TRACK:
Symptoms / Neuroscience**

PLENARY ROOM

(each talk: 14 min + 4 min discussion)

Chairs: Didier Attaix, Clermont-Ferrand, France
Daniel Marks, Portland, USA

- 72. **Neuropeptides and cachexia**
Herbert Herzog, Sydney, Australia
- 73. **PThrP and cachexia**
Akihiro Asakawa, Kagoshima, Japan
- 74. **Role of change in neuromuscular junction: Agrin and neurotrypsin in muscle wasting**
Denis Guttridge, Columbus, USA
- 75. **Sensor control of cancer cachexia**
Michael Meguid, Syracuse, USA
- 76. **Symptoms and symptom generation in cachexia**
Andrew Coats, Norwich, UK



JUDGES' CHOICE: Oral presentations of selected abstracts (clinical & nutrition science)

SALA CRISTALLO

(talk No. 77 & 78: 15 min + 5 min discussion; all other talks: 7 min + 3 min discussion)

Chairs: Michael Meguid, Syracuse, USA
Stephan von Haehling, Berlin, Germany

- 77. **Review: Economic cost of sarcopenia and hunger in the United States**
Donald Shepard, Waltham, USA
- 78. **Review: COPD cachexia**
Matthias John, Schwedt, Germany
- 79. **Association of the surrogate measures of dietary protein intake and survival in 100,088 chronic hemodialysis patients (6-04)**
Kamyar Kalantar-Zadeh, Torrance, USA
- 80. **The association of body mass index and presence of cachexia with survival and disability after stroke: data from 1521 hospitalised patients with 30 months follow-up (2-15)**
Wolfram Doehner, Berlin, Germany
- 81. **Autonomic nervous system dysfunction in cancer cachexia patients is predominantly sympathetic (4-22)**
Thomas Hundsberger, St. Gallen, Switzerland
- 82. **The feasibility and acceptability of neuromuscular electrical stimulation (NMES) in patients with advanced cancer (8-10)**
Tamara Windholz, Montreal, Canada
- 83. **Parenteral nutrition in patients with cancer cachexia and bowel obstruction: International survey on indications, outcomes and practices (6-08)**
Karen Nestor, St. Gallen, Switzerland

12:15–13:15

Challenges to identify endpoints for drug development in wasting diseases**SALA CRISTALLO**

A panel discussion organized by the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).

Lunch will be provided

Panelists: Stefan Anker, Berlin, Germany
 Matthias John, Schwedt, Germany
 John Morley, St. Louis, USA
 Giuseppe Rosano, Rome, Italy
 Gerald Sokol, Bethesda, USA

13:30–14:45

PLENARY SESSION: Debates and updates**PLENARY ROOM**

(each talk: 12 min + 3 min discussion)

Chairs: William Evans, Research Triangle Park, USA
 Vickie Baracos, Edmonton, Canada

84. Pro Belgian Blue

Ken Fearon, Edinburgh, UK

85. Pro Kobe Beef

John Morley, St. Louis, USA

86. Nutrition and inflammation

Filippo Rossi Fanelli, Rome, Italy

87. Cachexia and cardio-renal-anemia syndrome

Kamyar Kalantar-Zadeh, Los Angeles, USA

88. Highlights from our journal: editor's choice

Stephan von Haehling, Berlin, Germany

14:45-15:15

Coffee break

15:15 - 16:30

PLENARY SESSION: Congress highlights**PLENARY ROOM**

(each talk: 12 min + 3 min discussion)

Chairs: Giuseppe Rosano, Rome, Italy
 Filippo Rossi Fanelli, Rome, Italy
 Akio Inui, Kagoshima, Japan
 John Morley, St. Louis, USA

89. Basic science

Denis Guttridge, Columbus, USA

90. Sarcopenia

William Evans, Research Triangle Park, USA

91. Nutritional therapies

Maurizio Muscaritoli, Rome, Italy

92. Treatment of cachexia

Stefan Anker, Berlin, Germany

Awards ceremony

Poster award

Faculty

Angela Abbatecola, Ancona, Italy
Volker Adams, Leipzig, Germany
Stefan Anker, Berlin, Germany
Josep Argiles, Barcelona, Spain
Akihiro Asakawa, Kagoshima, Japan
Didier Attaix, Clermont-Ferrand, France
Vickie Baracos, Edmonton, AB, Canada
Samuel Breit, Sydney, Australia
Tommy Cederholm, Uppsala, Sweden
Chih-Yen Chen, Taipei, Taiwan
Andrew Coats, Norwich, UK
Steven Cummings, San Francisco, CA, USA
Francesco Dioguardi, Milan, Italy
Wolfram Doehner, Berlin, Germany
William Evans, Research Triangle Park, NC, USA
Ken Fearon, Edinburgh, UK
Serguei Fetissov, Rouen, France
John Friend, Bridgewater, NJ, USA
David Glass, Cambridge, MA, USA

Bret Goodpaster, Pittsburgh, PA, USA
Paul Greenhaff, Nottingham, UK
Denis Guttridge, Columbus, OH, USA
HQ Han, Thousand Oaks, CA, USA
Tamara Harris, Bethesda, MD, USA
Herbert Herzog, Sydney, Australia
Takashi Higashiguchi, Tsu, Japan
Kim Anh Hoang, Hochiminh, Vietnam
Akio Inui, Kagoshima, Japan
Aminah Jatoi, Rochester, MN, USA
Kamyar Kalantar-Zadeh, Los Angeles, CA, USA
Friedrich Koehler, Berlin, Germany
Mitja Lainscak, Golnik, Slovenia
Ramon Langen, Maastricht, The Netherlands
Lars Larsson, Uppsala, Sweden
Alessandro Laviano, Rome, Italy
Gordon Lynch, Melbourne, Australia
Robert Mak, La Jolla, CA, USA
Fady Malik, San Francisco, CA, USA
Giovanni Mantovani, Monserrato, Cagliari, Italy
Daniel Marks, Portland, OR, USA
Michael Meguid, Syracuse, NY, USA
John Morley, St. Louis, MO, USA

Maurizio Muscaritoli, Rome, Italy
Hiroaki Nanba, Kobe, Japan
Marco Narici, Manchester, UK
Giuseppe Rosano, Rome, Italy
Filippo Rossi Fanelli, Rome, Italy
Ronenn Roubenoff, Boston, MA, USA
Alan Russell, Research Triangle Park, NC, USA
Donald Shepard, Waltham, MA, USA
Cornel Sieber, Nuremberg, Germany
Gerald Sokol, Bethesda, MD, USA
Jochen Springer, Berlin, Germany
Mitch Steiner, Memphis, TN, USA
Florian Strasser, St. Gallen, Switzerland
Koichi Takayama, Fukuoka, Japan
Thomas Thum, Hannover, Germany
Carsten Tschöpe, Berlin, Germany
Yasuhito Uezono, Tokyo, Japan
Bruno Vellas, Toulouse, France
Stephan von Haehling, Berlin, Germany
Jean Woo, Hong Kong, China
Frederick Wu, Manchester, UK
Tiansun Xu, Research Triangle Park, NC, USA



anamorelin
Now Enrolling

The ROMANA Phase III Clinical Trials

Pivotal Trials of a Novel Oral Treatment for Cancer Cachexia

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C

Primary endpoints

- Lean body mass
- Muscle strength


Secondary endpoints

- Body weight
- Quality of life
- Overall survival

For more information or to discuss becoming an investigator, please see a Helsinn representative.

FLOOR PLAN

MAIN AREA – GARDEN LEVEL



SYMPOSIA AREA – GROUND LEVEL



SPONSORS:

- 1 – Fresenius Kabi
- 2 – Thermo Scientific
- 3 – Danone (Nutricia)
- 4 – Helsinn
- 5 – Abbott

7th CACHEXIA CONFERENCE



KOBE/OSAKA JAPAN

9-11 December 2013

For further information visit
www.cachexia.org



ACKNOWLEDGMENTS

The Society on Sarcopenia, Cachexia and Wasting Disorders would like to thank the following sponsors for their significant support in organizing its 6th Conference.





Shaping alliances, building pharmaceuticals

KYOWA KIRIN



Sarcopenic patients need to **rebuild** muscle strength

Introducing **new** FortiFit

An innovation in sarcopenia management

New FortiFit is a food for special medical purposes developed for the dietary management of sarcopenia, the age-related loss of muscle mass, strength and function. FortiFit contains a unique blend of high concentration leucine, other essential amino acids and vitamin D. Essential amino acids, including leucine, are important to stimulate muscle protein synthesis intended to help improve muscle strength and function.¹ www.nutricia.com



For your sarcopenic patients: **recommend FortiFit**

NUTRICIA
Advanced Medical Nutrition